Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 7
1981 9
1982 39
1983 20
1984 29
1985 22
1986 24
1987 29
1988 32
1989 46
1990 56
1991 75
1992 100
1993 103
1994 131
1995 149
1996 133
1997 166
1998 252
1999 261
2000 236
2001 276
2002 305
2003 296
2004 300
2005 328
2006 305
2007 312
2008 320
2009 319
2010 337
2011 347
2012 357
2013 324
2014 367
2015 381
2016 378
2017 388
2018 390
2019 375
2020 462
2021 452
2022 428
2023 394
2024 436
2025 467
2026 108

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,112 results

Results by year

Filters applied: . Clear all
Page 1
Symbicort Turbuhaler: a new concept in asthma management.
Kuna P, Kuprys I. Kuna P, et al. Int J Clin Pract. 2002 Dec;56(10):797-803. Int J Clin Pract. 2002. PMID: 12510955 Review.
Symbicort is a novel asthma product containing both budesonide and formoterol in a single inhaler, Turbuhaler. ...Clinical studies have shown that Symbicort is more effective in the treatment of asthma than double-dose corticosteroid, and clinical expe …
Symbicort is a novel asthma product containing both budesonide and formoterol in a single inhaler, Turbuhaler. ...Clini …
Symbicort: controlling asthma in adults.
Lalloo U. Lalloo U. Respir Med. 2002 Feb;96 Suppl A:S16-22. Respir Med. 2002. PMID: 11858561 Free article. Review.
Symbicort Turbuhaler (budesonide/formoterol in a single inhaler) is one such development. Studies to date in over 800 adult patients have confirmed that budesonide/formoterol is superior to double the dose of budesonide monotherapy and at …
Symbicort Turbuhaler (budesonide/formoterol in a single inhaler) is one such development. Studies to date in over 800 a …
Symbicort: a pharmacoeconomic review.
Halpin DM. Halpin DM. J Med Econ. 2008;11(2):345-62. doi: 10.3111/13696990802210984. J Med Econ. 2008. PMID: 19450091 Free article.
OBJECTIVE: This systematic review examines the published evidence on the pharmacoecomonics of Symbicort. Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. …
OBJECTIVE: This systematic review examines the published evidence on the pharmacoecomonics of Symbicort. Symbicort is a com …
Symbicort: controlling asthma in children.
Tal A. Tal A. Respir Med. 2002 Feb;96 Suppl A:S23-8. Respir Med. 2002. PMID: 11858562 Free article. Review.
This paper presents data to show that the combined administration of budesonide and formoterol via a single inhaler (Symbicort Turbuhaler) is effective and well tolerated in the treatment of asthma in children....
This paper presents data to show that the combined administration of budesonide and formoterol via a single inhaler (Symbic …
Symbicort Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines.
Lin J, Zhou X, Wang C, Liu C, Cai S, Huang M. Lin J, et al. Expert Rev Respir Med. 2018 Mar;12(3):191-202. doi: 10.1080/17476348.2018.1429921. Epub 2018 Feb 5. Expert Rev Respir Med. 2018. PMID: 29400090 Review.
Areas covered: Randomized controlled trials and real-world evidence demonstrate that flexibly dosed budesonide/formoterol for maintenance and relief (Symbicort Maintenance And Reliever Therapy [SMART]) is associated with reductions in severe exacerbations, pr …
Areas covered: Randomized controlled trials and real-world evidence demonstrate that flexibly dosed budesonide/formoterol for …
A Practical Guide to Implementing SMART in Asthma Management.
Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. Reddel HK, et al. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S31-S38. doi: 10.1016/j.jaip.2021.10.011. Epub 2021 Oct 16. J Allergy Clin Immunol Pract. 2022. PMID: 34666208 Review.
For both steps 3 and 4, patients take additional inhalations of budesonide-formoterol 160/4.5 mug, one inhalation whenever needed for symptom relief, up to a maximum for adults and adolescents of 12 total inhalations in any single day (delivering 54 mug formotero …
For both steps 3 and 4, patients take additional inhalations of budesonide-formoterol 160/4.5 mug, one inhalation whenever nee …
The whole story: treatment outcomes with Symbicort.
Zetterström, Buhl R, Mellem H, Andersson F. Zetterström, et al. Respir Med. 2002 Feb;96 Suppl A:S29-35. Respir Med. 2002. PMID: 11858563 Free article. Review.
Against this background, we have assessed the cost-effectiveness of Symbicort (budesonide and formoterol in a single inhaler), a treatment that provides better control of asthma compared with budesonide alone. ...Combined long-term therapy with bude …
Against this background, we have assessed the cost-effectiveness of Symbicort (budesonide and formoterol in a single in …
Are Seretide and Symbicort useful in COPD?
[No authors listed] [No authors listed] Drug Ther Bull. 2004 Mar;42(3):18-21. doi: 10.1136/dtb.2004.42318. Drug Ther Bull. 2004. PMID: 15038079 Review.
Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) an …
Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers …
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.
Beasley R, Bruce P, Houghton C, Hatter L. Beasley R, et al. J Allergy Clin Immunol Pract. 2023 Mar;11(3):762-772.e1. doi: 10.1016/j.jaip.2023.01.002. Epub 2023 Jan 10. J Allergy Clin Immunol Pract. 2023. PMID: 36639054 Free article. Review.
The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta(2)-agonists as reliever therapy in adolescents and adults with asthma, across the range of asthma severity. ...In this commentary, we review …
The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta(2 …
10,112 results
You have reached the last available page of results. Please see the User Guide for more information.